Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 18/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12666433 | 0.81 | HRH3 (0.50) | HRH3KDM4EALDH1A1CYP3A4HPGD | |
| SCHEMBL1857487 | 0.78 | HRH3 (0.54) | HRH3KMT2A | |
| SCHEMBL1861242 | 0.72 | HRH3 (0.60) | HRH3KMT2A | |
| SCHEMBL26192208 | 0.66 | HRH3 (0.41) | HRH3HRH2HRH1KDM4EKMT2A | |
| SCHEMBL106758 | 0.66 | L3MBTL1 (0.43) | KDM4EALDH1A1KMT2A | |
| SCHEMBL171991 | 0.66 | SMN1; SMN2 (0.40) | KDM4EALDH1A1 | |
| SCHEMBL13451316 | 0.64 | TDP1 (0.49) | HRH3ALDH1A1KMT2A | |
| SCHEMBL17828027 | 0.64 | L3MBTL1 (0.48) | KDM4EALDH1A1 | |
| SCHEMBL29550640 | 0.63 | HRH3 (0.52) | HRH3HRH2HRH1KMT2A | |
| SCHEMBL20333216 | 0.62 | CARM1 (0.50) | HRH3ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423147-B2 | Pyridine compounds as histamine H3 modulators | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2008-09-09 | — | — | US | claimed |
| EP-1761496-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3-RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-14 | — | — | EP | claimed |
| WO-2005097751-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3-RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-20 | — | — | WO | claimed |
| US-20050222151-A1 | Non-Imidazole heterocyclic compounds | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2005-10-06 | — | — | US | claimed |
| US-7947718-B2 | Isoxazole compounds as histamine H3 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-7947718-B2 | Isoxazole compounds as histamine H3 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-20100022539-A1 | Isoxazole Compounds as Histamine H3 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022539-A1 | Isoxazole Compounds as Histamine H3 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-28 | — | — | US | disclosed |
| US-20080306066-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | CARRUTHERS NICHOLAS I | 2008-12-11 | — | — | US | disclosed |
| US-20080306066-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | CARRUTHERS NICHOLAS I | 2008-12-11 | — | — | US | disclosed |
| US-7423147-B2 | Pyridine compounds as histamine H3 modulators | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2008-09-09 | — | — | US | disclosed |
| US-7423147-B2 | Pyridine compounds as histamine H3 modulators | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2008-09-09 | — | — | US | disclosed |
| EP-1761496-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3-RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005097751-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3-RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222151-A1 | Non-Imidazole heterocyclic compounds | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022539-A1 | Isoxazole Compounds as Histamine H3 modulators | HRH3, HRH4, HRH1 | HRH3 1/4885HRH2 4/4885HRH1 3/4885 |
| US-20050222151-A1 | Non-Imidazole heterocyclic compounds | HRH3, HRH4, HRH2 | HRH3 1/4885HRH2 3/4885HRH1 4/4885 |
| US-20080306066-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | HRH3, HRH4, HRH2 | HRH3 1/4885HRH2 3/4885HRH1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.